Research progress of protein induced by vitamin K absence or antagonist II in liver transplantation for hepatocellular carcinoma
Zheyu Zhou,
Qiaoyu Liu,
Jinsong Liu,
Wenwen Li,
Shuya Cao,
Jiawei Xu,
Jun Chen,
Xiaoliang Xu,
Chaobo Chen
Affiliations
Zheyu Zhou
Department of General Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China
Qiaoyu Liu
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
Jinsong Liu
Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Colorectal Cancer Research Center, Shanghai, China
Wenwen Li
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China
Shuya Cao
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Science, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, China
Jiawei Xu
Department of Hepatobiliary and Transplantation Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Jun Chen
Department of Pathology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China; Corresponding author.
Xiaoliang Xu
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Corresponding author.
Chaobo Chen
Department of General Surgery, Xishan People's Hospital of Wuxi City, Wuxi, China; Corresponding author.
Hepatocellular carcinoma (HCC) is the most common pathologic type of primary liver cancer. Liver transplantation (LT) is a radical strategy for treating patients with early-stage HCC, which may lead to a better prognosis compared to hepatectomy and ablation. However, survival of patients who develop HCC recurrence after LT is short, and early recurrence is the most common cause of death. Thus, efficient biomarkers are also needed in LT to guide precision therapy to improve patient prognosis and 5-year survival. Protein induced by vitamin K absence or antagonist II (PIVKA-II) is an abnormal prothrombin that cannot activate coagulation, and it is significantly increased in patients with HCC, obstructive jaundice, and those taking vitamin K antagonists. Over the past decades, substantial progress has been made in the study of PIVKA-II in diagnosing, surveilling, and treating HCC, but its role in LT still needs to be elaborated. In this review, we focused on the role of PIVKA-II as a biomarker in LT for HCC, especially its relationship with clinicopathologic features, early recurrence, long-term survival, and donor-recipient selection.
